/ /

Andrew Bowser
Dermatologists fail to screen patients for depression
Dermatologists should take ownership of screening patients for mental health concerns associated with their skin condition.
Revised tumor classification for head and neck CSCC
AJCC updates classifications for head and neck cutaneous squamous cell carcinoma. AJCC 8 expands criteria for cases that now qualify to be T3. Now, T3 and T4 capture more poor outcomes.
Oral antibiotic prescriptions remain high
Despite recommendations to limit the use of oral antibiotics, dermatologists continue to prescribe them in high numbers, according to results of a large, retrospective analysis of U.S. prescribing trends from 2004 to 2013.
Technology proves better than human eye in acne assessment
Dermatologist evaluations of patient acne photos submitted via smartphone compare favorably to in-person evaluations, a JAMA Dermatology study shows.
Clinical practice guideline authors fail to disclose all industry payments
Some authors of AAD clinical practice guidelines received sizable payments from industry that were not completely disclosed, JAMA Dermatology Reports.
Herpes zoster rates stay steady with biologics in psoriasis
Study shows no significant difference in herpes zoster risk between psoriasis patients receiving systemic therapy and those not receiving systemic therapy.
The top 25 psoriasis authors
In 2018 at just five days into the New Year, a search of PubMed revealed 86 new psoriasis studies. So, who is leading the pack?
A noteworthy margin of error in psoriasis?
Dermatologists need to be aware of margin of error and related issues that can affect the results of biosimilar clinical trials, a study shows.
A 1,854% price hike
The cost of doxycycline hyclate prescriptions increased 1,854% between 2011 and 2013 in a retrospective analysis of commercial claims data, and there was no association between market concentration and price of the oral antibiotic. Clinician or pharmacy level interventions to choose less costly oral tetracycline-class antibiotics could result in substantial cost savings.
Ocular comorbidities associated with atopic dermatitis
Ocular comorbidity risk is already high in patients with atopic dermatitis and may increase even further as biologic agents are introduced, a study shows.

Poll